RNatives has multiple programs in the research and development pipeline. The discovery process is driven by the utilization of our proprietary in silico discovery platform and subsequent in vitro validation and in vivo proof-of-concept studies. The discovery software enables rational design for creating modulators for target genes of choice. The discovered RNA can be synthesized, formulated, and tested with preferred RNA carriers for driving the formulation selection for the IND-enabling studies. Our lead program focuses on cardiovascular diseases for creating treatment of heart failure (HF) and peripheral artery disease (PAD). Our lead molecule is miR-466, which regulates VEGFA and has therefore angiogenic and regenerative properties. The current data supports fast track designation and breakthrough therapy status for our therapy.